Yaron Werber

Gilead Sciences, Inc. (NASDAQ: GILD) received new data from IMS Health about the breakdown of its drug prescriptions. Gilead is most known for its hepatitis C medications, Harvoni and Sovaldi. IMS prescription data breaks down how many people are receiving which drug prescriptions in more than...

In a report published Wednesday, Citigroup analyst Yaron Werber downgraded the rating on Agios Pharmaceuticals (NASDAQ: AGIO) from Buy to Neutral, but raised the price target from $93.00 to $137.00. In the report, Citigroup noted, “We are raising our AGIO target price to $137 based on recent...

In a report published Monday, Citigroup analyst Yaron Werber initiated coverage on Atara Biotherapeutics Inc (NASDAQ: ATRA) with a Buy rating and $37.00 price target. In the report, Citigroup noted, “We are initiating coverage of Atara Biotherapeutics with a Buy rating and a $37 target price. Atara...

Puma Biotechnology (NYSE: PBYI) has nearly tripled in value Wednesday on positive trial data for its lead breast cancer drug, while one analyst said the company is a likely takeover target. After the close Tuesday, the company said a Phase III clinical trial of its neratinib breast cancer drug...

Large-cap biotech stocks should see healthy second-quarter results driven by strong demand and new products, a Citi analyst said Thursday. Performance of the sector will look especially attractive in light of a weak first quarter, when the sector was held back by poor weather, health-care...

In a report published Sunday, Citi analyst Yaron Werber warns investors of upcoming challenges for Puma Biotechnology (NYSE: PBYI) following the announcement that the phase 2 monotherapy cohort of neratinib in HER2+ brain metastases failed to meet its primary endpoint. ASCO Meeting: PB272 Results...

Investors are fearful the launch of Gilead's (NASDAQ: GILD) HepC franchise has been too “rapid,” which will cause the drug's market share to plateau and decline. There are also concerns of reimbursement headwinds in state Medicaid programs “as CO, PA, and Utah have decided against reimbursing for...

In a report published Friday, Citi analyst Yaron Werber maintained a Buy rating on Intercept Pharmaceuticals (NASDAQ: ICPT), raising its price target from $60.00 to $400.00. According to the report, the new price target reflects a ~45 percent upside to yesterday's close. The increase is driven by...

In a report published Friday, Citigroup analyst Yaron Werber reiterated a Buy rating on Celgene (NASDAQ: CELG), and raised the price target from $182.00 to $204.00. In the report, Citigroup noted, “We conducted a detailed analysis and our key takeaway is that Revlimid/dex is set to dominate the...

In a report published Friday, Citigroup analyst Yaron Werber reiterated a Buy rating on Amgen (NASDAQ: AMGN), but lowered the price target from $139.00 to $131.00. In the report, Citigroup noted, “We conducted a detailed analysis of the myeloma market and conclude that Kyprolis/oprozomib are...

In a report published Wednesday, Citigroup analyst Yaron Werber reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD), and raised the price target from $85.00 to $87.00. In the report, Citigroup noted, “Gilead's stock has been posting impressive gains ahead of the much anticipated launch of...

In a report published Tuesday, Citigroup analyst Yaron Werber reiterated a Buy rating on Amgen (NASDAQ: AMGN), and raised the price target from $130.00 to $136.00. In the report, Citigroup noted, “Today's acquisition of Onyx at $125/sh ($9.7B net of Onyx cash) is a positive for Amgen given that...

Citi Investment Research & Analysis analyst Yaron Werber maintained a Buy/High Risk rating for shares of Genzyme Corporation (Nasdaq: GENZ), while lowering the stock's price target to $64 per share, down from the previous price target of $66. Werber said that Genzyme (GENZ) announced further (...

Citi Investment Research analyst Yaron Werber has kept the target price of $57 per share unchanged for Gilead Sciences Inc. (NASDAQ: GILD), stating that the consensus numbers look conservative and further upside is possible given Gilead’s substantial expense leverage and potential for a better top...